These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25840609)

  • 1. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
    Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy.
    Campbell BA; Hornby C; Cunninghame J; Burns M; MacManus M; Ryan G; Lau E; Seymour JF; Wirth A
    Ann Oncol; 2012 May; 23(5):1259-1266. PubMed ID: 21980193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.
    Mazonakis M; Lyraraki E; Damilakis J
    Med Phys; 2017 Jul; 44(7):3866-3874. PubMed ID: 28493609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
    Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy.
    Mulvihill DJ; McMichael K; Goyal S; Drachtman R; Weiss A; Khan AJ
    Radiother Oncol; 2014 Aug; 112(2):279-83. PubMed ID: 25082095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
    Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease.
    Kourinou KM; Mazonakis M; Lyraraki E; Papadaki HΑ; Damilakis J
    Phys Med; 2019 Jan; 57():100-106. PubMed ID: 30738513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma.
    Maraldo MV; Aznar MC; Vogelius IR; Petersen PM; Specht L
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1057-65. PubMed ID: 23200817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
    Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
    Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
    Ann Oncol; 2013 Aug; 24(8):2113-8. PubMed ID: 23619032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk.
    Koh ES; Tran TH; Heydarian M; Sachs RK; Tsang RW; Brenner DJ; Pintilie M; Xu T; Chung J; Paul N; Hodgson DC
    Radiat Oncol; 2007 Mar; 2():13. PubMed ID: 17362522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.
    Paumier A; Ghalibafian M; Beaudre A; Ferreira I; Pichenot C; Messai T; Lessard NA; Lefkopoulos D; Girinsky T
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):199-205. PubMed ID: 21481723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma.
    Houlihan OA; Ntentas G; Cutter DJ; Daly P; Gillham C; McArdle O; Duane FK
    Clin Transl Oncol; 2023 May; 25(5):1368-1377. PubMed ID: 36585562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma.
    Maraldo MV; Jørgensen M; Brodin NP; Aznar MC; Vogelius IR; Petersen PM; Berthelsen AK; Christensen CB; Hjalgrim LL; Specht L
    Pediatr Blood Cancer; 2014 Apr; 61(4):717-22. PubMed ID: 24660228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
    Weber DC; Peguret N; Dipasquale G; Cozzi L
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1578-86. PubMed ID: 19596171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.
    Rosenbrock J; Kaul H; Oertel M; Celik E; Linde P; Fan J; Eichenauer DA; Bröckelmann PJ; von Tresckow B; Kobe C; Dietlein M; Fuchs M; Borchmann P; Eich HT; Baues C
    Int J Radiat Oncol Biol Phys; 2024 Dec; 120(5):1344-1352. PubMed ID: 38631539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma.
    Maraldo MV; Brodin NP; Vogelius IR; Aznar MC; Munck Af Rosenschöld P; Petersen PM; Specht L
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1232-7. PubMed ID: 22270170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
    Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma.
    Hodgson DC; Koh ES; Tran TH; Heydarian M; Tsang R; Pintilie M; Xu T; Huang L; Sachs RK; Brenner DJ
    Cancer; 2007 Dec; 110(11):2576-86. PubMed ID: 17941006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.
    Filippi AR; Ragona R; Piva C; Scafa D; Fiandra C; Fusella M; Giglioli FR; Lohr F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):161-8. PubMed ID: 25863763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.